Pricing Log in Create free account
Friday 6 November 2026 Export IMNM’s income statement to Excel — free account

Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.

Revenue
+69.8%
EPS
−30.0%
Free cash flow
−27.0%

Quarter to June 2026, against a year earlier

18.77 0.86 +4.80%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
4/9
Altman Z
21.57
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Immunome, Inc. (IMNM) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Immunome, Inc. (IMNM) trades at a EV/Sales of 121×. Over the past ten years it has ranged from 0.0× (December 2023) to 227× (August 2026); the current reading is higher than 90% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 97.2× 116.42%
FY2024 44.9× 678.59%
FY2023 5.8× —

Quarterly newest first

Period EV/Sales Change
Jun 2025 43.0× 116.28%
Mar 2025 19.9× (55.69%)
Dec 2024 44.9× (29.00%)
Sep 2024 63.2× 50.42%
6 more quarters

Against its own ten years

Low 0.0× High 227×
Ten-year median 0.0×
Current reading's percentile 90

EV/Sales against peers

Company EV/Sales
LKFT Lakefront Biotherapeutics - Sponsored ADR compare −1.3×
VERA Vera Therapeutics, Inc. compare n/m
BHVN Biohaven Ltd. compare 2.2×
AUPH Aurinia Pharmaceuticals Inc compare 5.3×
ADMA ADMA Biologics Inc compare 5.8×
VCEL Vericel Corporation compare 7.6×
PVLA Palvella Therapeutics, Inc. compare 48.1×
IMNM Immunome, Inc. 121×
CLDX Celldex Therapeutics, Inc. compare 1,691×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on IMNM